Supernus Pharmaceuticals, Inc.
SUPN
$50.21
$0.300.60%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -38.55M | -19.12M | 64.50M | 61.91M | 73.87M |
| Total Depreciation and Amortization | 91.56M | 85.39M | 80.69M | 80.05M | 80.41M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 69.48M | 34.53M | 29.49M | 24.20M | 19.72M |
| Change in Net Operating Assets | -75.16M | -28.93M | 12.38M | -2.01M | -2.05M |
| Cash from Operations | 47.33M | 71.88M | 187.06M | 164.15M | 171.95M |
| Capital Expenditure | -1.34M | -1.12M | -1.20M | -804.00K | -725.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -293.09M | -293.09M | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 298.54M | 337.00M | -81.74M | -100.12M | -189.14M |
| Cash from Investing | 4.11M | 42.78M | -82.94M | -100.93M | -189.87M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 37.62M | 35.94M | 15.66M | 14.04M | 14.91M |
| Repurchase of Common Stock | -4.23M | -5.19M | -4.76M | -4.72M | -2.72M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -24.26M | -24.26M | -22.40M | -20.10M | -- |
| Cash from Financing | 9.13M | 6.49M | -11.50M | -10.78M | 12.19M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 60.57M | 121.15M | 92.62M | 52.45M | -5.72M |